TI
TEVA icon

TT International’s Teva Pharmaceuticals TEVA Stock Holding History

TT International’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-179,573
Closed -$5.96M – 48
2017
Q2 		$5.96M Buy
179,573
+4,827
+3% +$149K 1.4% 26
2017
Q1 		$5.61M Sell
174,746
-15,497
-8% -$529K 1.56% 28
2016
Q4 		$6.9M Sell
190,243
-748,351
-80% -$29.9M 2.13% 18
2016
Q3 		$43.2M Sell
938,594
-436,589
-32% -$22.8M 11.78% 2
2016
Q2 		$69.1M Buy
1,375,183
+109,780
+9% +$5.84M 23.24% 1
2016
Q1 		$67.7M Sell
1,265,403
-13,108
-1% -$769K 26.31% 1
2015
Q4 		$83.9M Buy
1,278,511
+73,046
+6% +$4.51M 32.81% 1
2015
Q3 		$68.1M Buy
1,205,465
+220,557
+22% +$14.3M 34.8% 1
2015
Q2 		$58.2M Sell
984,908
-346,433
-26% -$21.4M 45.28% 1
2015
Q1 		$82.9M Buy
1,331,341
+91,907
+7% +$5.34M 58.07% 1
2014
Q4 		$71.3M Buy
+1,239,434
New +$69.1M 44.45% 1

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

TT International's TEVA Position: Q3 2017 in Review

TT International sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 179,573 shares — an estimated $5.96M sold.

TT International first reported a position in TEVA in Q4 2014 and held it in 11 quarters. The position peaked at $83.9M in Q4 2015. 537 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • TT International reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • TT International sold 179,573 Teva Pharmaceuticals shares in Q3 2017, an estimated $5.96M.
  • TT International first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 11 quarters.
  • TT International's Teva Pharmaceuticals position peaked at $83.9M in Q4 2015.
  • 537 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on TT International's 13F filing for Q3 2017, filed 15 Nov 2017.